Skip to main content
. 2021 Sep 23;58(3):2003927. doi: 10.1183/13993003.03927-2020

FIGURE 2.

FIGURE 2

Variability in a) modified Medical Research Council (mMRC) dyspnoea grade (available for 96.5% of patients), b) St George's Respiratory Questionnaire (SGRQ) total score (available for 69.3% of patients) and c) Chronic Airways Assessment Test (CAAT#) total score (available for 70.0% of patients) by physician-assigned diagnosis and severity. For b and c, boxes represent the median (interquartile range (Q1–Q3); whiskers extend to 1.5 times the interquartile range, with circles representing individual outliers. COPD: chronic obstructive pulmonary disease. #: the CAAT is a trademark of the GlaxoSmithKline group of companies. © 2009 GlaxoSmithKline. All rights reserved. It has been modified from the COPD Assessment Test, with permission, by replacement of the term “COPD” with “chronic airways” and “pulmonary disease” in the questionnaire title and instruction, respectively. : recruitment was stratified by diagnosis/severity with the aim of achieving similar numbers of patients in each group; for patients with asthma+COPD, the severity category is the worse of the two physician-assessed severity classifications, and patients with COPD classified as “very severe” were included in the “severe” group.